Compare · AXGN vs CBLL
AXGN vs CBLL
Side-by-side comparison of Axogen Inc. (AXGN) and CeriBell Inc. (CBLL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXGN and CBLL operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- AXGN is the larger of the two at $2.09B, about 2.0x CBLL ($1.06B).
- Over the past year, AXGN is up 108.7% and CBLL is up 97.2% - AXGN leads by 11.5 points.
- AXGN has been more active in the news (6 items in the past 4 weeks vs 2 for CBLL).
- AXGN has more recent analyst coverage (11 ratings vs 8 for CBLL).
- Company
- Axogen Inc.
- CeriBell Inc.
- Price
- $34.65-2.74%
- $25.05-9.40%
- Market cap
- $2.09B
- $1.06B
- 1M return
- -23.49%
- +0.08%
- 1Y return
- +108.70%
- +97.17%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- News (4w)
- 6
- 2
- Recent ratings
- 11
- 8
Axogen Inc.
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Latest AXGN
- Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026
- BofA Securities initiated coverage on AxoGen with a new price target
- Barclays initiated coverage on AxoGen with a new price target
- Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week
- Axogen Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair
- SEC Form 424B5 filed by Axogen Inc.
- Amendment: Axogen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Axogen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock
Latest CBLL
- Chief Technology Officer Woo Raymond exercised 4,887 shares at a strike of $3.65 and sold $119,145 worth of shares (4,887 units at $24.38) as part of a pre-agreed trading plan (SEC Form 4)
- Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis
- President and CEO Chao Xingjuan sold $521,775 worth of shares (20,846 units at $25.03) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 746,345 units (SEC Form 4)
- Chief Financial Officer Blumberg Scott sold $21,150 worth of shares (846 units at $25.00) as part of a pre-agreed trading plan and exercised 846 shares at a strike of $9.41 (SEC Form 4)
- Senior VP, Finance and PAO Foehr David sold $224,451 worth of shares (9,255 units at $24.25) as part of a pre-agreed trading plan and exercised 7,500 shares at a strike of $4.70, decreasing direct ownership by 5% to 34,144 units (SEC Form 4)
- Chief Technology Officer Woo Raymond exercised 13,276 shares at a strike of $2.76 and sold $118,901 worth of shares (4,887 units at $24.33) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 203,118 units (SEC Form 4)
- President and CEO Chao Xingjuan sold $973,079 worth of shares (39,540 units at $24.61) as part of a pre-agreed trading plan and exercised 25,000 shares at a strike of $4.70, decreasing direct ownership by 2% to 767,191 units (SEC Form 4)
- Chief Financial Officer Blumberg Scott exercised 652 shares at a strike of $9.41 and sold $16,300 worth of shares (652 units at $25.00) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Revenue Officer Manni Joseph S. sold $32,691 worth of shares (1,361 units at $24.02), decreasing direct ownership by 2% to 55,956 units (SEC Form 4) (tax liability)
- Senior VP, Finance and PAO Foehr David sold $44,425 worth of shares (1,852 units at $23.99) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 35,899 units (SEC Form 4) to cover withholding tax